RecruitingNCT06751030

Community, Home-based Education, Screening Services Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria

Community, Home-based Education, Screening Services (CHESS) Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria


Sponsor

Emory University

Enrollment

1,500 participants

Start Date

Dec 3, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims: * Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population. * Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity. * Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program's maintenance and sustainability.


Eligibility

Sex: FEMALEMin Age: 25 YearsMax Age: 50 Years

Inclusion Criteria1

  • \- Patients must be able to perform vaginal self-collection as well as give informed consent

Exclusion Criteria6

  • Male gender
  • Age \<25 or \>50
  • Unknown or negative HIV status
  • Pregnancy
  • Hysterectomy
  • Inability to give informed consent Inability/refusal to perform vaginal self-collection

Interventions

BEHAVIORALThe Mother Mentor program

The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care

DIAGNOSTIC_TESTGeneXpert HPV test

A cervical cancer screening tool.


Locations(3)

APIN Health Initiatives

Abuja, Nigeria

University of Ibadan

Ibadan, Nigeria

Nigeria Institute of Medical Research (NIMR

Lagos, Nigeria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06751030


Related Trials